The data “shows that our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose,” Paul Stoffels, chief scientist of the drugmaker, said in the release. “The results give us confidence as we move forward in the development of our vaccines and our high-end manufacturing.”
J&J aims to embark on the final phase of testing in September, compressing the traditional timeline as it battles others such as GlaxoSmithKline Plc and AstraZeneca Plc in an attempt to end the pandemic. The action rose 1.3% in trading before the US stock exchanges opened.
J&J, who received a $ 456 million grant from the Biomedical Advanced Research and Development Authority, has already entered into discussions with the United States, the European Union and governments around the world on the provision of its vaccine s he was successful in the clinic. The company has yet to determine a price for its shot, although senior executives suggest it will be offered on a not-for-profit basis for the duration of the pandemic.
Technology from the New Brunswick, New Jersey-based drug maker is based on human adenovirus, a type of cold virus. This is an approach that is perhaps best known for its use in an Ebola vaccine.